Regencell Bioscience Holdings Limited (RGC)
USD 34.1
(5.87%)
USD 34.1
(5.87%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 8.43 Million USD | -33.15% |
| 2023 | 12.62 Million USD | -29.95% |
| 2022 | 18.01 Million USD | 5197.59% |
| 2021 | 340.13 Thousand USD | -33.83% |
| 2020 | 514.01 Thousand USD | 111.26% |
| 2019 | 243.3 Thousand USD | -99.99% |
| 2018 | 2.84 Billion USD | 7.45% |
| 2017 | 2.64 Billion USD | 0.51% |
| 2016 | 2.63 Billion USD | 3.65% |
| 2015 | 2.53 Billion USD | 0.0% |
| 2013 | 2.7 Billion USD | 22.41% |
| 2012 | 2.2 Billion USD | -11.36% |
| 2011 | 2.49 Billion USD | -5.5% |
| 2010 | 2.63 Billion USD | 1.49% |
| 2009 | 2.59 Billion USD | 0.0% |
| 2007 | 2.63 Billion USD | 6.73% |
| 2006 | 2.46 Billion USD | -2.91% |
| 2005 | 2.54 Billion USD | 2.87% |
| 2004 | 2.47 Billion USD | 0.0% |
| 2002 | 2.31 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.47 Million USD | -17.01% |
| 2024 Q2 | 10.47 Million USD | 0.0% |
| 2024 Q4 | 8.43 Million USD | 0.0% |
| 2023 Q1 | 15.54 Million USD | -13.71% |
| 2023 Q2 | 15.54 Million USD | 0.0% |
| 2023 Q4 | 12.62 Million USD | 0.0% |
| 2023 FY | 12.62 Million USD | -29.95% |
| 2023 Q3 | 12.62 Million USD | -18.82% |
| 2022 Q4 | 18.01 Million USD | 0.0% |
| 2022 FY | 18.01 Million USD | 5197.59% |
| 2022 Q3 | 18.01 Million USD | -14.45% |
| 2022 Q1 | 21.06 Million USD | 6092.53% |
| 2022 Q2 | 21.06 Million USD | 0.0% |
| 2021 Q1 | 600.37 Thousand USD | 16.8% |
| 2021 FY | 340.13 Thousand USD | -33.83% |
| 2021 Q4 | 340.13 Thousand USD | 0.0% |
| 2021 Q2 | 600.37 Thousand USD | 0.0% |
| 2021 Q3 | 340.13 Thousand USD | -43.35% |
| 2020 Q3 | 514.01 Thousand USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 514.01 Thousand USD | 111.26% |
| 2020 Q4 | 514.01 Thousand USD | 0.0% |
| 2019 FY | 243.3 Thousand USD | -99.99% |
| 2018 Q1 | 2.67 Billion USD | -2.77% |
| 2018 Q2 | 2.84 Billion USD | 6.39% |
| 2018 FY | 2.84 Billion USD | 7.45% |
| 2017 Q4 | 2.74 Billion USD | 2.32% |
| 2017 Q1 | 2.47 Billion USD | -3.7% |
| 2017 Q2 | 2.64 Billion USD | 6.78% |
| 2017 Q3 | 2.68 Billion USD | 1.53% |
| 2017 FY | 2.64 Billion USD | 0.51% |
| 2016 Q1 | 2.4 Billion USD | -7.02% |
| 2016 FY | 2.63 Billion USD | 3.65% |
| 2016 Q4 | 2.57 Billion USD | -0.71% |
| 2016 Q3 | 2.59 Billion USD | -1.56% |
| 2016 Q2 | 2.63 Billion USD | 9.26% |
| 2015 FY | 2.53 Billion USD | 0.0% |
| 2015 Q1 | 2.55 Billion USD | -4.57% |
| 2015 Q4 | 2.59 Billion USD | 4.29% |
| 2015 Q3 | 2.48 Billion USD | -2.17% |
| 2015 Q2 | 2.53 Billion USD | -0.55% |
| 2014 Q2 | 2.7 Billion USD | 7.83% |
| 2014 Q4 | 2.67 Billion USD | -4.0% |
| 2014 Q3 | 2.78 Billion USD | 3.05% |
| 2014 Q1 | 2.5 Billion USD | -3.84% |
| 2013 FY | 2.7 Billion USD | 22.41% |
| 2013 Q4 | 2.6 Billion USD | 6.39% |
| 2013 Q2 | 2.2 Billion USD | 0.52% |
| 2013 Q3 | 2.45 Billion USD | 10.97% |
| 2013 Q1 | 2.19 Billion USD | -4.69% |
| 2012 Q2 | 2.34 Billion USD | 3.51% |
| 2012 FY | 2.2 Billion USD | -11.36% |
| 2012 Q4 | 2.3 Billion USD | -0.03% |
| 2012 Q3 | 2.3 Billion USD | -1.46% |
| 2012 Q1 | 2.26 Billion USD | -4.47% |
| 2011 Q2 | 2.49 Billion USD | -6.65% |
| 2011 Q1 | 2.67 Billion USD | 3.7% |
| 2011 Q3 | 2.32 Billion USD | -6.8% |
| 2011 FY | 2.49 Billion USD | -5.5% |
| 2011 Q4 | 2.36 Billion USD | 1.92% |
| 2010 Q1 | 2.51 Billion USD | -5.1% |
| 2010 Q3 | 2.58 Billion USD | -1.88% |
| 2010 Q4 | 2.57 Billion USD | -0.5% |
| 2010 Q2 | 2.63 Billion USD | 5.0% |
| 2010 FY | 2.63 Billion USD | 1.49% |
| 2009 FY | 2.59 Billion USD | 0.0% |
| 2009 Q1 | 2.55 Billion USD | -4.87% |
| 2009 Q2 | 2.59 Billion USD | 1.64% |
| 2009 Q3 | 2.56 Billion USD | -1.39% |
| 2009 Q4 | 2.64 Billion USD | 3.28% |
| 2008 Q4 | 2.68 Billion USD | 2.09% |
| 2008 Q2 | 2.63 Billion USD | 1.58% |
| 2008 Q3 | 2.63 Billion USD | -0.04% |
| 2008 Q1 | 2.59 Billion USD | -3.14% |
| 2007 Q4 | 2.67 Billion USD | -13.2% |
| 2007 FY | 2.63 Billion USD | 6.73% |
| 2007 Q3 | 3.08 Billion USD | 24.96% |
| 2007 Q2 | 2.46 Billion USD | 4.66% |
| 2007 Q1 | 2.35 Billion USD | -3.95% |
| 2006 Q4 | 2.45 Billion USD | 0.78% |
| 2006 Q3 | 2.43 Billion USD | -3.79% |
| 2006 Q2 | 2.53 Billion USD | 4.37% |
| 2006 Q1 | 2.42 Billion USD | -1.78% |
| 2006 FY | 2.46 Billion USD | -2.91% |
| 2005 Q2 | 2.54 Billion USD | 4.72% |
| 2005 FY | 2.54 Billion USD | 2.87% |
| 2005 Q1 | 2.42 Billion USD | -2.0% |
| 2005 Q3 | 2.46 Billion USD | -3.22% |
| 2005 Q4 | 2.47 Billion USD | 0.4% |
| 2004 FY | 2.47 Billion USD | 0.0% |
| 2004 Q2 | 2.47 Billion USD | 5.64% |
| 2004 Q1 | 2.33 Billion USD | -24.65% |
| 2004 Q4 | 2.47 Billion USD | 3.64% |
| 2004 Q3 | 2.39 Billion USD | -3.28% |
| 2003 Q4 | 3.1 Billion USD | 35.02% |
| 2003 Q1 | 2.33 Billion USD | -0.26% |
| 2003 Q2 | 2.31 Billion USD | -0.99% |
| 2003 Q3 | 2.29 Billion USD | -0.48% |
| 2002 Q3 | 2.2 Billion USD | 0.0% |
| 2002 FY | 2.31 Billion USD | 0.0% |
| 2002 Q4 | 2.33 Billion USD | 5.88% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | 87.272% |
| Safety Shot Inc | 12.7 Million USD | 33.605% |
| Bright Green Corporation | 17.4 Million USD | 51.513% |
| Embecta Corp. | 1.21 Billion USD | 99.305% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 99.067% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 85.304% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 99.262% |
| Dynavax Technologies Corporation | 997.09 Million USD | 99.154% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 95.9% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 98.841% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 99.464% |
| PainReform Ltd. | 9.93 Million USD | 15.023% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 69.144% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 69.144% |
| SCYNEXIS, Inc. | 128.41 Million USD | 93.429% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | 63.514% |
| Journey Medical Corporation | 76.84 Million USD | 89.02% |
| Alpha Teknova, Inc. | 128.58 Million USD | 93.438% |
| Procaps Group, S.A. | 460.18 Million USD | 98.166% |
| Theratechnologies Inc. | 77.76 Million USD | 89.15% |
| Harrow Health, Inc. | 311.75 Million USD | 97.293% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | 43.341% |
| Biofrontera Inc. | 27.93 Million USD | 69.79% |
| DURECT Corporation | 45.18 Million USD | 81.327% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 99.401% |
| Cronos Group Inc. | 1.13 Billion USD | 99.256% |
| OptiNose, Inc. | 107.72 Million USD | 92.167% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 98.209% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 84.918% |
| RedHill Biopharma Ltd. | 23.04 Million USD | 63.387% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 98.166% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | 29.199% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 89.681% |
| Radius Health, Inc. | 1.71 Billion USD | 99.508% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 84.165% |
| ProPhase Labs, Inc. | 91.92 Million USD | 90.821% |
| Phibro Animal Health Corporation | 982.18 Million USD | 99.141% |
| Procaps Group S.A. | 460.18 Million USD | 98.166% |
| Alvotech | 950.09 Million USD | 99.112% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 80.516% |
| Viatris Inc. | 47.68 Billion USD | 99.982% |
| Rockwell Medical, Inc. | 52.17 Million USD | 83.826% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 92.855% |
| SIGA Technologies, Inc. | 254.83 Million USD | 96.689% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.805% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 96.917% |
| Shineco, Inc. | 84.17 Million USD | 89.976% |
| PetIQ, Inc. | 868.22 Million USD | 99.028% |
| Incannex Healthcare Limited | 17.04 Million USD | 50.5% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.74% |
| Alimera Sciences, Inc. | 153.52 Million USD | 94.504% |
| Silver Spike Investment Corp. | 88.57 Million USD | 90.474% |
| Assertio Holdings, Inc. | 286.41 Million USD | 97.054% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -41.777% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | 75.032% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | 72.992% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | 36.304% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 96.769% |
| Hempacco Co., Inc. | 18.04 Million USD | 53.233% |
| Talphera, Inc. | 20.39 Million USD | 58.626% |
| Alvotech | 950.09 Million USD | 99.112% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 97.922% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 99.489% |
| Currenc Group, Inc. | 141.49 Million USD | 94.036% |
| Kamada Ltd. | 351.96 Million USD | 97.603% |
| Indivior PLC | 1.95 Billion USD | 99.568% |
| Evoke Pharma, Inc. | 7.06 Million USD | -19.377% |
| Flora Growth Corp. | 23.62 Million USD | 64.284% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | 36.304% |
| Evolus, Inc. | 188.99 Million USD | 95.535% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 99.341% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 99.442% |
| Akanda Corp. | 8.83 Million USD | 4.545% |